The global uterine cancer market size was valued at USD 6.57 billion in 2025 and is projected to grow from USD 6.9 billion in 2026 to USD 10.2 billion by 2034 at a CAGR of 5% during the forecast period 2026-2034. North America dominated the uterine cancer market with a market share of 42.5% in 2025.
Uterine cancer is a type of cancer that develops in the tissues of the uterus, most commonly in the endometrium (the inner lining of the uterus). The uterine cancer market includes diagnostic tests, surgical procedures, radiation therapy, chemotherapy, hormone therapy, targeted therapies, and immunotherapies used to detect, treat, and manage the disease. Market growth is driven by the rising incidence of uterine cancer, increasing awareness, and advancements in personalized cancer treatment.
Download a Free Sample To learn more about this report,
Growing Adoption of Immunotherapy and Targeted Therapies for Advanced Uterine Cancer
The global uterine cancer market is witnessing a significant shift toward immunotherapy and targeted therapies as they improve treatment outcomes for patients with advanced and recurrent disease. Healthcare providers are increasingly combining immune checkpoint inhibitors with chemotherapy to enhance progression-free survival while reducing disease recurrence. At the same time, precision medicine approaches using biomarker testing, such as mismatch repair (dMMR) and microsatellite instability (MSI), are helping physicians select the most effective therapies for individual patients. These advances are improving personalized cancer care and expanding treatment options beyond conventional chemotherapy.
Such developments highlight the growing preference for immunotherapy-based treatment strategies in uterine cancer management.
Increasing Use of Companion Diagnostics for Personalized Treatment
The uterine cancer market is also experiencing rapid growth in companion diagnostic testing, enabling clinicians to identify patients who are most likely to benefit from targeted therapies. Molecular testing for biomarkers such as MSI and mismatch repair status is becoming a standard part of clinical practice, supporting more accurate treatment selection and improving patient outcomes. As precision oncology continues to advance, diagnostic innovations are playing an increasingly important role in personalized uterine cancer care.
Such innovations demonstrate the increasing importance of precision diagnostics in improving the effectiveness of uterine cancer treatment.
Rising Incidence of Uterine Cancer and Advancements in Early Diagnosis
The uterine cancer market is primarily driven by the increasing incidence of endometrial cancer, particularly among aging women and individuals with obesity, diabetes, and hormonal disorders. Growing awareness of women's health, expanding cancer screening programs, and advances in molecular diagnostics are improving early detection rates. Additionally, continuous developments in targeted therapies, immunotherapies, and minimally invasive surgical procedures are enhancing treatment outcomes and driving market growth.
High Cost of Advanced Cancer Therapies and Limited Access
The uterine cancer market faces restraints due to the high costs associated with advanced targeted therapies, immunotherapies, and precision diagnostic tests. Many innovative treatments remain expensive, limiting accessibility in low- and middle-income countries. Additionally, delayed diagnosis, unequal healthcare infrastructure, and reimbursement limitations continue to hinder the widespread adoption of advanced treatment options. Stringent regulatory approval processes and lengthy clinical trials also delay the introduction of novel therapies into the market.
Expanding Adoption of Precision Medicine and Immunotherapy
The uterine cancer market trends present significant opportunities through the increasing adoption of precision medicine, biomarker-based diagnostics, and immunotherapy. Advances in genomic profiling are enabling personalized treatment strategies that improve clinical outcomes while reducing unnecessary therapies. The growing number of clinical trials evaluating novel checkpoint inhibitors, antibody-drug conjugates, and targeted therapies is expected to expand treatment options for patients with advanced or recurrent uterine cancer.
Late-Stage Diagnosis and Treatment Accessibility
The uterine cancer market continues to face challenges due to delayed diagnosis and unequal access to specialized oncology care. Many patients in low-resource settings are diagnosed at advanced stages, reducing treatment success rates and increasing healthcare costs. Limited availability of molecular diagnostic testing, oncology specialists, and advanced treatment facilities further restricts optimal patient management. In addition, the high cost of innovative therapies and disparities in reimbursement policies continue to affect treatment accessibility across different regions.
Request Customizationto receive a tailored report.
Endometrial Adenocarcinoma Dominated the Market with 68.4% Share in 2025
The endometrial adenocarcinoma segment accounted for the largest share of the global uterine cancer market at 68.4% in 2025, with a market value of USD 4.49 billion, and is projected to grow at a CAGR of 6.61% during the forecast period. The segment leads due to its high prevalence among uterine cancer cases and increasing awareness of early diagnosis and treatment.
Therapeutic Treatment Dominated the Market with 39.8% Share in 2025
The therapeutic treatment segment held the largest market share of 39.8% in 2025, reaching a value of USD 2.61 billion, and is expected to grow at a CAGR of 7.16% during 2026–2034. The segment is driven by the growing adoption of targeted therapies, chemotherapy, and personalized treatment approaches for uterine cancer patients.
Endometrial Biopsy Dominated the Market with 31.4% Share in 2025
The endometrial biopsy segment accounted for the largest share of 31.4% in 2025, with a market value of USD 2.06 billion, and is projected to grow at a CAGR of 6.74%. Its widespread use as the primary diagnostic method for confirming uterine cancer supports its leading position in the market.
Hormone Therapy is Projected to Register the Fastest Growth at a CAGR of 7.61%
The hormone therapy segment is expected to register the highest CAGR of 7.61% during the forecast period, supported by increasing use of hormone-based treatments for hormone-sensitive uterine cancers and growing demand for less invasive treatment options with improved patient outcomes.
Hysterectomy Dominated the Market with 78.3% Share in 2025
The hysterectomy segment dominated the surgery category with a 78.3% market share in 2025, valued at USD 5.14 billion, and is projected to grow at a CAGR of 6.18%. Hysterectomy remains the standard surgical treatment for most uterine cancer cases due to its effectiveness in removing cancerous tissue and reducing disease recurrence.
Hospitals Dominated the Market with 48.7% Share in 2025
The hospitals segment held the largest share of 48.7% in 2025, with a market value of USD 3.20 billion, and is expected to grow at a CAGR of 6.92% during the forecast period. Hospitals continue to dominate due to the availability of advanced diagnostic technologies, multidisciplinary cancer care teams, and comprehensive treatment facilities.
Speak to an Analystto discuss market opportunities.
North America held the largest share of the global uterine cancer market, accounting for 42.5% in 2025 with a market value of USD 2.79 billion. The regional market is expected to grow at a CAGR of 6.32% during the forecast period. Growth is driven by the high prevalence of uterine cancer, increasing awareness of early diagnosis, widespread availability of advanced diagnostic technologies, and strong adoption of targeted therapies and minimally invasive surgical procedures. Well-established healthcare infrastructure and favorable reimbursement policies further support market expansion.
The United States is the leading market in North America due to the high incidence of uterine cancer, advanced oncology care infrastructure, and increasing adoption of precision medicine. Rising investments in cancer research, expanding access to immunotherapies and targeted treatments, and the presence of leading pharmaceutical and medical device companies continue to drive market growth. Government-supported cancer screening and awareness initiatives also contribute to early diagnosis and improved treatment outcomes.
Canada is experiencing steady market growth due to increasing awareness of gynecologic cancers, improved access to specialized oncology services, and growing adoption of advanced diagnostic technologies. Government healthcare programs, expanding cancer screening initiatives, and continuous investments in cancer treatment facilities are supporting the demand for uterine cancer diagnosis and treatment solutions.
Europe accounted for 28.4% of the global uterine cancer market in 2025, representing a market value of USD 1.87 billion. The market is projected to grow at a CAGR of 7.91% during the forecast period. Growth is supported by an aging female population, increasing incidence of endometrial cancer, favorable healthcare policies, and rising adoption of innovative cancer therapies. Strong investments in oncology research and improved access to personalized treatment options continue to strengthen market growth across the region.
The United Kingdom is witnessing significant growth due to increasing government efforts to improve cancer diagnosis and treatment services. The adoption of advanced imaging technologies, molecular diagnostics, and minimally invasive surgical procedures is enhancing patient outcomes. Continued investments in cancer research and national awareness campaigns are also contributing to market expansion.
Germany represents one of Europe's leading uterine cancer markets owing to its advanced healthcare system, strong oncology research capabilities, and widespread availability of innovative treatment options. Increasing use of targeted therapies, robotic-assisted surgeries, and precision diagnostics is supporting market growth. The country's well-developed reimbursement framework further encourages access to advanced cancer care.
Asia Pacific held 19.6% of the global uterine cancer market in 2025, with a market value of USD 1.29 billion. The regional market is expected to grow at a CAGR of 7.38% during the forecast period. Growth is driven by improving healthcare infrastructure, rising awareness of women's health, increasing cancer screening programs, and expanding access to advanced oncology treatments. Rapid healthcare investments and growing adoption of modern diagnostic technologies are further supporting market expansion.
Japan is a key market in Asia Pacific due to its aging population, advanced healthcare infrastructure, and high adoption of innovative cancer therapies. Increasing focus on early diagnosis, precision medicine, and minimally invasive surgical techniques is driving demand for uterine cancer treatment. Continuous research in oncology and improvements in personalized healthcare further support market growth.
China is experiencing rapid market growth due to its large patient population, expanding healthcare infrastructure, and increasing government investments in cancer care. Rising awareness of women's health, growing availability of advanced diagnostic technologies, and expanding access to targeted therapies are supporting the adoption of uterine cancer treatment solutions across the country.
Latin America accounted for 5.7% of the global uterine cancer market in 2025, representing a market value of USD 0.37 billion. The market is projected to grow at a CAGR of 5.96% during the forecast period. Increasing healthcare investments, expanding cancer awareness programs, and improving access to diagnostic and treatment services are supporting market growth. Governments are also focusing on strengthening oncology care infrastructure across the region.
Brazil is the largest uterine cancer market in Latin America, supported by its expanding healthcare infrastructure and increasing focus on cancer diagnosis and treatment. Rising awareness of gynecologic cancers, growing adoption of minimally invasive surgeries, and improved access to oncology care are contributing to market expansion. Government initiatives promoting early cancer detection further support demand for diagnostic and therapeutic solutions.
The Middle East and Africa accounted for 3.8% of the global uterine cancer market in 2025, with a market value of USD 0.25 billion. The market is expected to grow at a CAGR of 5.42% during the forecast period. Growth is supported by improving healthcare infrastructure, increasing awareness of women's cancers, and expanding investments in oncology services. The adoption of advanced diagnostic technologies and greater access to specialized cancer treatment centers are contributing to regional market development.
The UAE is emerging as a significant market due to increasing healthcare expenditure, expanding oncology centers, and growing adoption of advanced cancer diagnostics and treatment technologies. Government initiatives focused on early cancer detection and improved access to specialized healthcare services are supporting market growth.
Africa is witnessing gradual growth in the uterine cancer market due to improving healthcare access, increasing awareness of gynecologic cancers, and expanding cancer screening initiatives. Investments in oncology infrastructure, enhanced diagnostic capabilities, and collaborations to strengthen cancer care services are expected to support future market growth across the region.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com